IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel
Rhea-AI Summary
IceCure Medical (Nasdaq: ICCM) has submitted a regulatory approval filing to Israel's Ministry of Health for its next-generation XSense™ System and CryoProbes. The application covers multiple indications already approved for ProSense®, including general surgery, dermatology, neurology, thoracic surgery, ENT, gynecology, oncology, proctology, and urology.
The company has already secured FDA marketing authorization for the XSense™ System. The filing aligns with growing trends in surgical de-escalation and increasing adoption of minimally invasive cryoablation procedures. The global minimally invasive surgery market is projected to grow at a 17% CAGR between 2022-2029, reaching $174 billion by 2029.
Positive
- FDA marketing authorization already secured for XSense™ System
- Broad range of approved indications covering multiple medical specialties
- Operating in a market projected to reach $174 billion by 2029 with 17% CAGR
Negative
- None.
Insights
The regulatory submission for XSense™ in Israel marks a significant milestone in IceCure's market expansion strategy, building upon their existing FDA approval. This next-generation single cryoprobe system represents an evolution in their technology portfolio, potentially offering improved operational efficiency and clinical outcomes across multiple specialties.
The filing's scope is particularly noteworthy, encompassing nine distinct medical specialties including oncology, general surgery, and specialized procedures. This broad-spectrum approach is strategically important for three reasons:
- It maximizes the potential revenue streams across different medical departments and healthcare settings
- It reduces dependency on any single medical specialty, creating a more resilient business model
- It positions IceCure to capture a larger share of the rapidly growing minimally invasive surgery market
The timing of this filing is particularly strategic, coinciding with the global healthcare trend toward minimally invasive procedures. With the market projected to reach
The regulatory process in Israel typically serves as a valuable reference point for other international markets, particularly in the Middle East and parts of Asia. A successful approval could accelerate regulatory pathways in other jurisdictions, potentially creating a domino effect for market access. The company's existing FDA approval for XSense™ provides a strong foundation for regulatory confidence, potentially expediting the Israeli approval process.
From a commercial perspective, the expansion of IceCure's product portfolio with XSense™ could drive market penetration through two key mechanisms: offering healthcare providers more options within their cryoablation platform and potentially capturing new market segments that may have specific requirements not met by their current ProSense® system.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Application covering a wide range of indications is in line with trends in de-escalation of surgery and growth in minimally invasive cryoablation procedures, pointing to strong potential for increasing demand
The filing contains a request for approval of all indications for which ProSense® has already received approval in
"As a leader in liquid-nitrogen based cryoablation technologies, we continue to innovate and bring to market healthcare advancements that support the global move toward de-escalation of surgery and the substantial increase in minimally invasive surgery procedures," stated IceCure's Chief Executive Officer, Eyal Shamir. "While de-escalation of surgery is a trend specific to the treatment of breast cancer, we see growing opportunities for our cryoablation systems to offer minimally invasive solutions in a wide range and expanding number of indications. We are optimistic about receiving regulatory clearance for XSense™ in
The global minimally invasive surgery market is forecast to grow by a CAGR of
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: the Company's view that opportunities for its cryoablation systems are growing in a wide range and expanding number of indications; the impending decision on regulatory clearance for XSense™ in
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
Logo - https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/icecure-submits-filing-for-regulatory-approval-of-its-next-generation-xsense-cryoablation-system-in-israel-302383227.html
SOURCE IceCure Medical